NASDAQ: VNDA Vanda Pharmaceuticals Inc. 8-K

Vanda stockholders approve equity plan expansion at 2026 annual meeting

Filed June 5, 2026 · Period ending June 4, 2026 · ~1 min read

Key Changes

  • medium

    Stockholders approved expanding the 2016 Equity Incentive Plan share pool, increasing shares available for future employee and executive compensation grants. This provides management flexibility for talent retention but may dilute existing shareholders.

  • low

    Three Class II directors elected to serve until 2029: Richard W. Dugan, Charles C. Duncan Ph.D., and Anne Sempowski Ward. All received majority stockholder support.

  • low

    Say-on-pay vote passed with 91% approval (35.2M for vs 3.2M against), indicating stockholder support for executive compensation practices. Vote is advisory and non-binding.

1 more material change plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.

Partner

Trade VNDA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 8, 2026 4:36 AM